BSRBR-RA Study · clinical trials is low and there is no evidence that tocilizumab increase the...
4
BSRBR-RA Study · clinical trials is low and there is no evidence that tocilizumab increase the risk of such events. However, in view of the observed increase of lipid levels, cardiovascular
![Australian public assessment for Tocilizumab [Actemra] · 2018. 6. 13. · Therapeutic Goods Administration AusPAR Actemra Tocilizumab PM-2016-03548-1-3 Final 4 June 2018 Page 2 of](https://img.pdfslide.us/doc/110x75/5ffb5d82da40706da41be6f3/australian-public-assessment-for-tocilizumab-actemra-2018-6-13-therapeutic.jpg)
